GlassScriptPhysician profile
Marla Tucker
NPI 1881928703
$1,885.50
in general payments reported to CMS, 2019-2025
24 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $415 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $626.21 | 2024-2025 | Airsupra, Breztri |
| Abbott Laboratories | $283.43 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $143.49 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $99.21 | 2024-2025 | |
| Abbvie INC. | $73.13 | 2025 | |
| Ardelyx, INC. | $71.29 | 2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.18 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Organon LLC | $62.09 | 2024-2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.77 | 2024-2025 | Xifaxan |
| Lundbeck LLC | $57.01 | 2024-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $47.29 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $45.51 | 2025 | Rexulti |
| Esperion Therapeutics, INC. | $33.48 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $31.99 | 2025 | Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $28.48 | 2025 | The Cologuard Plus Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $21.67 | 2025 | Voquezna |
| Ibsa Pharma INC. | $20.10 | 2025 | Flector, Licart, Tirosint |
| Ucb, INC. | $19.13 | 2024 | Rystiggo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.35 | 2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $17.76 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $15.30 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2024 | Austedo Xr |
| Electromed, INC. | $13.62 | 2025 | Smartvest |
| Currax Pharmaceuticals LLC | $13.52 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.